Delivered strong full year 2025 results Completed Initial Public Offering Introduced full year 2026 guidance Fourth quarter net sales of $7.8 ...

A new study reveals that the next generation of blockchain defenses will not rely on fixed rules alone but on adaptive, learning-based systems capable of evolving alongside intelligent adversaries.

Q4 2025 Earnings Call February 24, 2026 10:00 AM ESTCompany ParticipantsChris BrandonMichael Miles - Chairman of the Board ...

Q4 2025 Earnings Call February 26, 2026 7:30 AM ESTCompany ParticipantsSean Washchuk - Senior VP & CFOGeoffrey Martin ...

Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the ...

Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 - - Raised Proceeds of $200 Million in ...

C3.ai, Inc. ("C3 AI," "C3," or the "Company") (NYSE: AI), the Enterprise AI application software company, today announced ...

Daily biometrics, smart scales and AI companions are quietly rewriting the rules of aging.

Delivered strong full year 2025 resultsCompleted Initial Public OfferingIntroduced full year 2026 guidanceFourth quarter net sales of $7.8 billion, an increase of 14.8%Fourth quarter net income of $18 ...

Market valued at $1.45B in 2024 grows at 10.4% CAGR driven by biocompatible hemostatic solutions in surgical and trauma ...

Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of ...

All you have to do is steer.